Trials / Completed
CompletedNCT00184080
Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
A Multicenter Open-Label Non-Randomized Phase II Study of Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- University of Southern California · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety of an experimental drug called Elsamitrucin in people with non-Hodgkin's lymphoma and to see if it can shrink their tumors. Elsamitrucin has not been approved by the Food and Drug Administration (FDA). However, the FDA is permitting the use of this drug for this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Elsamitrusin |
Timeline
- Start date
- 2004-05-01
- Primary completion
- 2006-04-01
- Completion
- 2006-04-01
- First posted
- 2005-09-16
- Last updated
- 2014-05-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00184080. Inclusion in this directory is not an endorsement.